EP3976068A4 - CYTOKIN COCKTAILS FOR SELECTIVE EXPANSION OF T-CELL SUBSETS - Google Patents

CYTOKIN COCKTAILS FOR SELECTIVE EXPANSION OF T-CELL SUBSETS Download PDF

Info

Publication number
EP3976068A4
EP3976068A4 EP20814747.0A EP20814747A EP3976068A4 EP 3976068 A4 EP3976068 A4 EP 3976068A4 EP 20814747 A EP20814747 A EP 20814747A EP 3976068 A4 EP3976068 A4 EP 3976068A4
Authority
EP
European Patent Office
Prior art keywords
cytokin
cocktails
cell subsets
selective expansion
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20814747.0A
Other languages
German (de)
French (fr)
Other versions
EP3976068A1 (en
Inventor
Catherine Mary BOLLARD
Patrick Hanley
Christopher LAZARSKI
Michael Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens National Medical Center Inc
Original Assignee
Childrens National Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens National Medical Center Inc filed Critical Childrens National Medical Center Inc
Publication of EP3976068A1 publication Critical patent/EP3976068A1/en
Publication of EP3976068A4 publication Critical patent/EP3976068A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP20814747.0A 2019-05-31 2020-06-01 CYTOKIN COCKTAILS FOR SELECTIVE EXPANSION OF T-CELL SUBSETS Pending EP3976068A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855889P 2019-05-31 2019-05-31
PCT/US2020/035618 WO2020243729A1 (en) 2019-05-31 2020-06-01 Cytokine cocktails for selective expansion of t cell subsets

Publications (2)

Publication Number Publication Date
EP3976068A1 EP3976068A1 (en) 2022-04-06
EP3976068A4 true EP3976068A4 (en) 2023-08-09

Family

ID=73553344

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20814747.0A Pending EP3976068A4 (en) 2019-05-31 2020-06-01 CYTOKIN COCKTAILS FOR SELECTIVE EXPANSION OF T-CELL SUBSETS

Country Status (2)

Country Link
EP (1) EP3976068A4 (en)
WO (1) WO2020243729A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Interleukin-18 variants and methods of use
EP4259163A2 (en) * 2020-12-09 2023-10-18 Tevogen Bio Inc. Virus specific t-cells and methods of treating and preventing viral infections
WO2022195096A1 (en) * 2021-03-19 2022-09-22 Charité - Universitätsmedizin Berlin Peptide and method for direct analysis of sars-cov-2 immune responses
WO2022212505A1 (en) * 2021-03-30 2022-10-06 Arizona Board Of Regents On Behalf Of Arizona State University Optimal production of sars-cov-2 virus-like particles (vlps) produced in mammalian cells
EP4395805A1 (en) * 2021-09-03 2024-07-10 International N&H Denmark ApS Microbial cross-reactive antigens for use in the stimulation of t-cells
CN114578048B (en) * 2021-12-22 2023-08-08 重庆医科大学附属儿童医院 T lymphocyte development subgroup immunophenotyping method and kit
GR1010557B (en) * 2022-05-04 2023-10-16 Νοσοκομειο Γεωργιος Παπανικολαου, SARS-COV-2-SPECIFIC T LYMPHOCYTES FOR TREATMENT OF COVID-19
CN116694828A (en) * 2023-08-01 2023-09-05 北京大学人民医院 Application of detection reagent, CD3+ T cell anti-infection capability assessment method and product

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119947A1 (en) * 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2017049291A1 (en) * 2015-09-18 2017-03-23 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
WO2017075571A1 (en) * 2015-10-30 2017-05-04 Children's National Medical Center Generating hpv antigen-specific cells from a naive t cell population

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102625832A (en) * 2009-08-24 2012-08-01 贝勒医学院 Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses
EP2532740A1 (en) * 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
WO2016183350A1 (en) * 2015-05-13 2016-11-17 Terumobct, Inc. Cell expansion
MX2019000180A (en) * 2016-06-28 2019-11-05 Geneius Biotechnology Inc T cell compositions for immunotherapy.
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119947A1 (en) * 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2017049291A1 (en) * 2015-09-18 2017-03-23 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
WO2017075571A1 (en) * 2015-10-30 2017-05-04 Children's National Medical Center Generating hpv antigen-specific cells from a naive t cell population

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020243729A1 *

Also Published As

Publication number Publication date
WO2020243729A1 (en) 2020-12-03
EP3976068A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
EP3976068A4 (en) CYTOKIN COCKTAILS FOR SELECTIVE EXPANSION OF T-CELL SUBSETS
DK3897833T3 (en) Inhibitors of APOL1 and methods of using the same
EP4231561C0 (en) PROCEDURES TO SUPPORT SIDELINK REDISTRIBUTION
EP3857756C0 (en) SIGNAL FOR REPEAT
DK3507386T3 (en) Methods and apparatus which increase the efficiency of sequencing with binding
HUE059594T2 (en) Methods for purification of messenger RNA
IL286233A (en) Methods and systems for sequencing reads
DK3185868T3 (en) Novel ULK1 inhibitors and methods of using the same
CR20180013A (en) ANTI-TAU ANTIBODIES AND METHODS OF USE.
IL268944A (en) Method of replicating or amplifying circular dna
EP3464689A4 (en) SYSTEM AND METHOD FOR GROWING GROUP IIIA NITRIDE
DK3607050T3 (en) EX VIVO CULTURE SYSTEM AND METHODS FOR THE USE OF THE SAME
MA55478A (en) BICYCLIC HPK1 INHIBITORS
MA55477A (en) HPK1 INHIBITORS
EP3868889A4 (en) METHODS OF ACTIVATION/PROLIFERATION OF T-CELLS
DK3606929T3 (en) BETA-NICOTINATE ESTER NUCLEOTIDES AND METHODS FOR THE PREPARATION OF THE SAME
EP3864811C0 (en) METHOD FOR REDUCING PEAK-TO-AVERAGE POWER RATIO OF DM-RS SIGNALS
EP3752278C0 (en) METHOD FOR REDUCING BIOFILM AND SPORES FROM MEMBRANES
IL280772A (en) Multiplex testing of nucleic acids
DK3630772T3 (en) METHODS OF MAKING AND USING PDE9 INHIBITORS
DK3120055T3 (en) Membrane and method of making the same
DK3277742T3 (en) FLUORESCENT SILOXANELASTOMES, METHOD OF MANUFACTURE THIS AND USE
EP3458448A4 (en) METHODS OF USING FASN INHIBITORS
DK3307878T3 (en) METHODS FOR THE PREPARATION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS
EP3634266A4 (en) SYSTEM FOR THE REMOVAL OF SCOTS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230707

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20230704BHEP

Ipc: C07K 14/54 20060101ALI20230704BHEP

Ipc: C07K 14/005 20060101ALI20230704BHEP

Ipc: A61K 39/215 20060101ALI20230704BHEP

Ipc: A61K 39/12 20060101ALI20230704BHEP

Ipc: A61K 38/00 20060101ALI20230704BHEP

Ipc: A61K 35/17 20150101AFI20230704BHEP